JP6892820B2 - 卵巣癌を検出する方法 - Google Patents

卵巣癌を検出する方法 Download PDF

Info

Publication number
JP6892820B2
JP6892820B2 JP2017516994A JP2017516994A JP6892820B2 JP 6892820 B2 JP6892820 B2 JP 6892820B2 JP 2017516994 A JP2017516994 A JP 2017516994A JP 2017516994 A JP2017516994 A JP 2017516994A JP 6892820 B2 JP6892820 B2 JP 6892820B2
Authority
JP
Japan
Prior art keywords
acid
small molecule
concentration
ovarian cancer
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017516994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535756A5 (cg-RX-API-DMAC7.html
JP2017535756A (ja
Inventor
ミカ ヒルヴォ
ミカ ヒルヴォ
Original Assignee
ゾラ バイオサイエンシーズ オサケ ユキチュア
ゾラ バイオサイエンシーズ オサケ ユキチュア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾラ バイオサイエンシーズ オサケ ユキチュア, ゾラ バイオサイエンシーズ オサケ ユキチュア filed Critical ゾラ バイオサイエンシーズ オサケ ユキチュア
Publication of JP2017535756A publication Critical patent/JP2017535756A/ja
Publication of JP2017535756A5 publication Critical patent/JP2017535756A5/ja
Application granted granted Critical
Publication of JP6892820B2 publication Critical patent/JP6892820B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017516994A 2014-10-02 2015-10-02 卵巣癌を検出する方法 Active JP6892820B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20145855 2014-10-02
FI20145855 2014-10-02
PCT/FI2015/050654 WO2016051020A1 (en) 2014-10-02 2015-10-02 Methods for detecting ovarian cancer

Publications (3)

Publication Number Publication Date
JP2017535756A JP2017535756A (ja) 2017-11-30
JP2017535756A5 JP2017535756A5 (cg-RX-API-DMAC7.html) 2018-11-29
JP6892820B2 true JP6892820B2 (ja) 2021-06-23

Family

ID=55629471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516994A Active JP6892820B2 (ja) 2014-10-02 2015-10-02 卵巣癌を検出する方法

Country Status (10)

Country Link
US (1) US10534001B2 (cg-RX-API-DMAC7.html)
EP (1) EP3201623B1 (cg-RX-API-DMAC7.html)
JP (1) JP6892820B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170061704A (cg-RX-API-DMAC7.html)
CN (1) CN106716127B (cg-RX-API-DMAC7.html)
AU (1) AU2015326756A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017006593A2 (cg-RX-API-DMAC7.html)
CA (1) CA2959832A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701875YA (cg-RX-API-DMAC7.html)
WO (1) WO2016051020A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351938A1 (en) * 2017-01-18 2018-07-25 BIOCRATES Life Sciences AG New biomarkers for assessing ovarian cancer
WO2019008009A1 (en) 2017-07-05 2019-01-10 Zora Biosciences Oy METHODS OF DETECTING OVARIAN CANCER
CN107656006A (zh) * 2017-09-08 2018-02-02 上海市东方医院 用于检测血清或者血浆中α‑羟基丁酸浓度的试剂盒和方法
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
WO2020160108A1 (en) * 2019-01-30 2020-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Lipid biomarkers for cancer screening and monitoring
CN111430030A (zh) * 2020-04-17 2020-07-17 武汉大学 生物标志物在卵巢癌评估中的应用方法及系统
CN114544848B (zh) * 2020-11-25 2023-04-28 中国科学院大连化学物理研究所 一种用于诊断卵巢上皮癌的血清脂质标志物组合物及试剂盒和其与应用
EP4246146A1 (en) * 2022-03-14 2023-09-20 Fundació Institut Mar d'Investigacions Mèdiques (IMIM) Method for diagnosing cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824555A (en) 1996-05-30 1998-10-20 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20040199819A1 (en) * 2001-08-10 2004-10-07 Jorg Dauerer Method for fast and local error correction in the event of the failure of individual physical corrections in bundled communication connections and communication system device for carrying out the method
US20040180387A1 (en) * 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050170441A1 (en) 2003-09-12 2005-08-04 Health Research, Inc. Early detection of cancer of specific type using 1HNMR metabonomics
WO2009052186A1 (en) * 2007-10-15 2009-04-23 Georgia Tech Research Corporation Metabolomics-based identification of disease-causing agents
US9213030B2 (en) 2008-01-28 2015-12-15 National University Of Singapore Lipid tumour profile
WO2009151967A1 (en) 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
JP4744618B2 (ja) * 2009-04-13 2011-08-10 シャープ株式会社 ガス成分検出装置
KR20120011042A (ko) * 2009-04-15 2012-02-06 샌포드-번햄 메디칼 리서치 인스티튜트 항아폽토시스 단백질의 나프탈렌계 억제제
EP2513653A1 (en) * 2009-10-09 2012-10-24 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
US20110114511A1 (en) * 2009-11-17 2011-05-19 Sjong Angele Apparatus for detecting volatile organic compounds and related methods
GB201016139D0 (en) 2010-09-24 2010-11-10 Univ Leuven Kath Cancer phosholipidome
FI20115576A0 (fi) * 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy Menetelmä Alzheimerin taudin diagnoimiseksi
US20140156573A1 (en) 2011-07-27 2014-06-05 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc

Also Published As

Publication number Publication date
AU2015326756A1 (en) 2017-05-11
CN106716127B (zh) 2020-12-08
CA2959832A1 (en) 2016-04-07
EP3201623A4 (en) 2018-07-25
EP3201623A1 (en) 2017-08-09
KR20170061704A (ko) 2017-06-05
EP3201623B1 (en) 2020-07-22
US20170285036A1 (en) 2017-10-05
JP2017535756A (ja) 2017-11-30
SG11201701875YA (en) 2017-04-27
WO2016051020A1 (en) 2016-04-07
BR112017006593A2 (pt) 2017-12-19
CN106716127A (zh) 2017-05-24
US10534001B2 (en) 2020-01-14

Similar Documents

Publication Publication Date Title
JP6892820B2 (ja) 卵巣癌を検出する方法
EP2863227B1 (en) Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease
JP5933432B2 (ja) 前立腺癌を診断する手段と方法
US20180196074A1 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
WO2011151252A2 (en) Means and methods for diagnosing pancreatic cancer in a subject
JP2017533413A (ja) 乳癌を評価するためのバイオマーカー
EP2480895B1 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP2023055806A (ja) 膵管腺癌の検出および処置のための方法
JP2013246080A (ja) 大腸がん検査方法
JP6998023B2 (ja) 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー
ES2688121T3 (es) Medios y procedimientos de diagnóstico de la reaparición de cáncer de próstata después de prostatectomía
JP2023533959A (ja) 前立腺がんの検出及び治療方法
Recber et al. Optimization and normalization strategies for long term untargeted HILIC-LC-qTOF-MS based metabolomics analysis: Early diagnosis of breast cancer
WO2010018165A1 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP2010266386A (ja) 患者由来の代謝物を使用したがんの検査方法
CN112881578A (zh) 一种用于肝癌预后风险评估的试剂盒及应用
US20210405054A1 (en) Methods for detecting ovarian cancer
Rakhshan et al. Applications of mass spectroscopy in understanding cancer proteomics
CN118006776A (zh) 早期肺腺癌标志物及其筛选方法、诊断模型、诊断装置
AU2024257583A1 (en) Method of diagnosis and treatment of pancreatic cancer
Lima GC-MS Metabolomic Studies in Prostate Cancer: A Novel Approach Using in Vitro Models

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210528

R150 Certificate of patent or registration of utility model

Ref document number: 6892820

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250